1. HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma
- Author
-
Seija Grénman, Liina Salminen, Kaisa Huhtinen, Sakari Hietanen, Olli Carpén, Johanna Hynninen, Kim Pettersson, Kamlesh Gidwani, HUSLAB, Precision Cancer Pathology, Department of Pathology, Olli Mikael Carpen / Principal Investigator, Medicum, Research Program in Systems Oncology, University of Helsinki, and Helsinki University Hospital Area
- Subjects
Oncology ,medicine.medical_specialty ,Multivariate analysis ,medicine.medical_treatment ,BIOMARKERS ,3122 Cancers ,PROGRESSION ,HE4 ,Disease ,GUIDELINES ,PREDICT ,030218 nuclear medicine & medical imaging ,CA125 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Ovarian carcinoma ,High grade serous ovarian carcinoma ,Biomarkers, Tumor ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Prospective cohort study ,Ovarian Neoplasms ,Chemotherapy ,PREOPERATIVE SERUM CA-125 ,business.industry ,Proteins ,Cancer ,Hematology ,General Medicine ,Prognosis ,medicine.disease ,CANCER ,Tumor Burden ,3. Good health ,CYTOREDUCTION ,Serous fluid ,CA-125 Antigen ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,Female ,Neoplasm Recurrence, Local ,business ,prognostic marker ,PROTEIN 4 HE-4 - Abstract
OBJECTIVE Human epididymis protein 4 (HE4) is a validated, complementary biomarker to cancer antigen 125 (CA125) for high grade serous ovarian carcinoma (HGSC). Currently, there are insufficient data on the utility of longitudinal HE4 measurement during HGSC treatment and follow up. We set to provide a comprehensive analysis on the kinetics and prognostic performance of HE4 with serial measurements during HGSC treatment and follow up. METHODS This prospective study included 143 patients with advanced HGSC (ClinicalTrials.gov identifier: NCT01276574). Serum CA125 and HE4 were measured at baseline, before each cycle of chemotherapy and during follow up until first progression. Baseline biomarker values were compared to the tumor load assessed during surgery and to residual disease. Biomarker nadir values and concentrations at progression were correlated to survival. RESULTS The baseline HE4 concentration distinguished patients with a high tumor load from patients with a low tumor load assessed during surgery (p
- Published
- 2020
- Full Text
- View/download PDF